Skip to main content
Erschienen in: BMC Infectious Diseases 1/2018

Open Access 01.12.2018 | Research article

Identification of genetic variants associated with dengue or West Nile virus disease: a systematic review and meta-analysis

verfasst von: Megan E. Cahill, Samantha Conley, Andrew T. DeWan, Ruth R. Montgomery

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2018

Abstract

Background

Dengue and West Nile viruses are highly cross-reactive and have numerous parallels in geography, potential vector host (Aedes family of mosquitoes), and initial symptoms of infection. While the vast majority (> 80%) of both dengue and West Nile virus infections result in asymptomatic infections, a minority of individuals experience symptomatic infection and an even smaller proportion develop severe disease. The mechanisms by which these infections lead to severe disease in a subset of infected individuals is incompletely understood, but individual host differences including genetic factors and immune responses have been proposed. We sought to identify genetic risk factors that are associated with more severe disease outcomes for both viruses in order to shed light on possible shared mechanisms of resistance and potential therapeutic interventions.

Methods

We applied a search strategy using four major databases (Medline, PubMed, Embase, and Global Health) to find all known genetic associations identified to date with dengue or West Nile virus disease. Here we present a review of our findings and a meta-analysis of genetic variants identified.

Results

We found genetic variations that are significantly associated with infections of these viruses. In particular we found variation within the OAS1 (meta-OR = 0.83, 95% CI: 0.69–1.00) and CCR5 (meta-OR = 1.29, 95% CI: 1.08–1.53) genes is significantly associated with West Nile virus disease, while variation within MICB (meta-OR = 2.35, 95% CI: 1.68–3.29), PLCE1 (meta-OR = 0.55, 95% CI: 0.42–0.71), MBL2 (meta-OR = 1.54, 95% CI: 1.02–2.31), and IFN-γ (meta-OR = 2.48, 95% CI: 1.30–4.71), is associated with dengue disease.

Conclusions

Despite substantial heterogeneity in populations studied, genes examined, and methodology, significant associations with genetic variants were found across studies within both diseases. These gene associations suggest a key role for immune mechanisms in susceptibility to severe disease. Further research is needed to elucidate the role of these genes in disease pathogenesis and may reveal additional genetic factors associated with disease severity.
Begleitmaterial
Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12879-018-3186-6) contains supplementary material, which is available to authorized users.
Abkürzungen
DENV
Dengue virus
DHF
Dengue Hemorrhagic Fever
DSS
Dengue Shock Syndrome
GWAS
genome-wide association studies
PRISMA
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
SNP
single nucleotide polymorphism
WNV
West Nile virus

Background

Dengue (DENV) and West Nile (WNV) viruses are mosquito-borne viruses in the Flaviviridae family, which also includes other viruses such as Zika and yellow fever. These viruses can cause disease with substantial public health impact. DENV and WNV are found in similar areas of the world, can be carried by the Aedes family of mosquitoes, have similar initial stages of infections and similar symptoms of mild febrile illness, and are highly cross-reactive; however, severe disease manifests differently for these two viruses [13]. West Nile Virus was first identified in Uganda in 1937, has been endemic in the United States since 1999 [4], and is estimated to have infected 3 million people [5]. While the majority of infections are asymptomatic, ~ 20% of infections lead to mild febrile disease in infected individuals and 1% of infected individual experience severe, neurological disease such as meningitis and encephalitis [6]. DENV has a vastly higher disease burden, with an estimated 50 million cases and 25,000 fatalities worldwide annually [7, 8]. The majority of DENV infections can be classified as asymptomatic or mild febrile illness, with approximately < 1% progressing to Dengue Hemorrhagic Fever (DHF) or Dengue Shock Syndrome (DSS). DHF is delineated from mild DENV febrile illness by the increase in vascular permeability, while DSS has the additional development of circulatory shock [7, 8].
For both WNV and DENV, known risk factors such as immune-compromised states or advanced age are associated with susceptibility to mild and severe disease [9, 10]. The mechanisms by which an infection leads to severe disease in a subset of all infected individuals is incompletely explained. Differing immune responses to infections, including elevated cytokine responses, have been proposed [1113] and we have recently shown that geographic location is not a driver of severity of WNV infection in a localized region [14]. In addition to similarities in the early stages of infection [1517], both viruses induce strong immune responses including chemokines (such as IL-8) and cytokines which up-regulate inflammatory reaction (such as TNF-α, IL-1, Il-6, and IFN-β) [1821]. Renewed interest in understanding flaviviral infection and disease susceptibility comes as climate change expands the number of individuals at risk of exposure to WNV and DENV [3, 22], and with outbreaks of related flaviviruses, most notably Zika [23, 24].
Genetic differences are additional explanations of individual susceptibility to symptomatic disease, and previous genome-wide association studies (GWAS) and candidate-gene studies have identified genetic factors associated with DENV or WNV disease pathogenesis. To assess the current state of knowledge on genetic variation associated with these flaviviral diseases, and to identify any shared features of anti-viral responses, we conducted a systematic review and meta-analysis of the published associations to date between genetic variants and development of DENV or WNV disease.

Methods

A systematic review of genetic factors and WNV or DENV disease was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Additional file 1) [25].

Search strategy

Medline, PubMed, Embase, and Global Health databases were used to search the literature. Search terms included West Nile or DENV and genetic factors; the same set of text words was used for all databases in conjunction with subject headings that were tailored for each database. The text word search specified West Nile or Dengue in the title, a genetic term in the title or abstract, and a human-related term in the title or abstract (Table 1). A sample search strategy is included in the appendix (Additional file 2). Case-control studies which examined at least one genetic factor associated with either viral disease were included. Studies on non-human (e.g., viral, mosquito) genetics and case reports on single patients were excluded. Reports published prior to May 2017 were included in the review. An ancestry search was done of references of selected studies to collect additional potentially relevant references.
Table 1
Text word selection for search of selected databases. Text words used for the search strategy, with one term from each column required in the title for the viral term, or in the title or abstract for the genetic and human terms
Viral terms
Genetic Factor terms
Human-related terms
• West Nile
• Dengue
▪ microsatellite(s)
▪ genetic variation
▪ genetic factor(s)
▪ genetic marker(s)
▪ genetic analysis/analyses
▪ SNP(s)
▪ single nucleotide polymorphism(s)
▪ copy number variant(s)
▪ genetic predisposition
▪ genetic susceptibility
▪ disease susceptibility
▪ GWAS
▪ genome-wide association study/studies
▪ genetic association(s)
▪ genetic association study/studies
▪ candidate gene study/studies
▪ genetic predisposition to disease
▪ susceptibility to disease
▪ genetic variability
▪ gene identity
▪ human
▪ man/men
▪ woman/women
▪ child/children
▪ teenager(s)
▪ middle-aged
▪ elderly
▪ infant(s)
▪ male(s)
▪ female(s)
▪ patient(s)
▪ participant(s)
▪ citizen(s)
▪ subject(s)
▪ case(s)
▪ control(s)

Study selection and data extraction

Two researchers reviewed the titles and abstracts of all studies and identified potentially relevant articles within Covidence with 98.6% consistency [26]. Discrepancies were resolved through re-review and mutual consensus. Both researchers read the full text of all of the selected potentially relevant articles and identified the final reports to be included in this review. Data sets were extracted without personal identifiers and organized into literature tables. The main fields included authors, year of publication, country, sample size, case and control group definitions, genotyping method, genes and genetic variants analyzed, genotype count data when available, odds ratios (OR), and statistical analysis method.
When two or more studies examined the same variants, we used the raw genotype data to calculate ORs with 95% confidence intervals using the R package Epitools [27]. When the raw genotype data were not available within the published papers, we requested the data sets from corresponding authors of the studies. Of the six authors contacted, three shared data, two indicated they no longer had access to the data, and one did not respond by date of submission. In order to make comparisons across the different DENV phenotypes used in the studies, we compared asymptomatic DENV infections and controls with all symptomatic infections (DENV fever, DENV hemorrhagic fever, and DENV shock syndrome). Using the genotype data, we calculated ORs for each study under a dominant model, recessive model, homozygote mutant versus homozygote wild-type, and heterozygote versus homozygote wild-type. We meta-analyzed the ORs using RevMan [28]. The genetic model with the most significant meta-OR is presented here. When this model was the homozygote mutant versus homozygote wild or the heterozygote versus homozygote wild, we included both of these models for that particular single nucleotide polymorphism (SNP).

Quality assessment

We assessed the quality of each study with the Newcastle-Ottawa Quality Assessment Scale for Case-Control Studies [29], which assesses each study’s selection, comparability, and exposure ascertainment approach.

Results

To identify all published research assessing the role of genetic variation with DENV or WNV disease, we executed the above search strategy and identified 633 published reports (Table 1, Fig. 1). Two researchers independently reviewed the titles and abstracts of these 633 papers and identified 104 papers for further full-text review in this meta-analysis (Additional file 3). One additional paper from 1987 was identified as pertinent during the ancestry search and was added to the review. The final analysis includes data from 87 of the 105 publications, following exclusion of 18 papers for cause (seven repeats, six conference abstracts, and five with an outcome other than disease severity). Reflecting the higher disease burden and longer research history of DENV virus, of these 87 papers selected, 74 studied DENV-infected populations and 13 focused on WNV.

HLA genetic variation associated with disease severity

Notably, 27 separate HLA alleles were examined by two or more research groups for an association with severe DENV disease (Additional file 4). Four research groups analyzed HLA alleles for an association with WNV disease (Additional file 5), however there was no overlap in the alleles studied. Although HLA variants show substantial contribution to disease outcome, significant variations in study design, data analysis platforms, data availability and presentation precluded our in-depth meta-analysis of these data.

Multiple genes are associated with severity of WNV infection

Previous reports of genetic associations with WNV disease severity focused on U.S. or Canadian populations and compared severe and non-severe infections. Overall, these studies identified 12 gene variants and significant findings include SNPs of multiple immune-related genes such as RFC1, SCN1A, and IRF3 (Table 2).
Table 2
Genetic variation significantly associated with West Nile virus disease. We include in this table all variants studied by two or more research groups and variants found to have a significant association by one research group
Gene
Genetic variant
Entrez Gene ID [31]
Major Allele
Minor Allele
Number of Cases
Number in Comparison Group
Country
Key Results
Included in meta-analysis
ANPEP
rs25651
290
T
C
560 severe
950 non-severe infections
US & Canada
0.69 odds of severe disease [59]
Noa
G
A
39 severe
61 controls
Israel
No significant association with disease [60]
CACNA1H
rs113802594
8912
A
G
1330 severe
919 non-severe infections
US & Canada
8.58 odds of encephalitis [61]
No
CCR5
CCR5 Δ32
1234
Δ32 deletion
560 severe
950 non-Severe infections
US & Canada
No significant association with disease [59]
Yes
Δ32 deletion
39 severe
61 controls
Israel
No significant association with disease [60]
Δ32 deletion
422 symptomatic
331 asymptomatic infections
US & Canada
No significant association with disease [62]
Δ32 deletion
634 infections
422 controls
US
No significant association with disease, but significant association with more severe disease (p = 0.0016) [46]
Δ32 deletion
395 symptomatic (two cohorts of 247 and 148)
1318 controls
US
Significantly associated with disease in two cohorts (OR = 4.4 [1.6–11.8] and OR = 9.1 [3.4–24.8]), and fatal outcomes in one cohort with OR = 13.2 [1.9–89.9] [63]
HERC5
rs148556308
51,191
A
G
1330 severe
919 non-severe infections
US & Canada
Significantly associated with severe disease (p-value = 6.5 × 10− 10) [61]
No
IRF3
rs2304207
3661
G
C
422 severe
331 asymptomatic infections
US
0.52 odds of symptomatic infection under dominant model [62]
Noa
G
C
39 severe
61 controls
Israel
No significant association with disease [60]
MIF
rs5844572
4282
5 or 6 CATT repeats
7 CATT repeats
518 severe
514 non-severe
US & Canada
1.73 odds of encephalitis among patients with high-expression allele as compared to all other types of WNV disease [64]
No
MX1
rs7280422
4599
C
G
39 severe
61 controls
Israel
4.05 odds of infection associated with variant allele [60]
Noa
C
G
422 severe
331 asymptomatic infections
US
0.25 odds of symptomatic infection under a recessive model [62]
OASL
rs3213545
8638
C
T
422 severe
331 asymptomatic infections
US
No significant association with disease [62]
Yes
C
T
39 severe
61 controls
Israel
1.85 (1.03–3.3) odds of infection [60]
C
T
33 symptomatic
60 controls
US
Significantly associated with disease (P < 0.004) [65]
OAS1
rs10774671
4938
A
G
422 severe
331 asymptomatic infections
US
No significant association with disease [62]
Yes
A
G
39 severe
61 controls
Israel
No significant association with disease [60]
A
G
501 seropositive
552 controls
US
1.6 [95% CI 1.2–2.0] odds of seroconversion [66]
OAS1
rs34137742
4938
C
T
422 severe
331 asymptomatic infections
US
9.79 [95% CI 3.60–26.61] odds of encephalitis and paralysis [62]
Yes
C
T
39 severe
61 controls
Israel
No significant association with disease [60]
RFC1
rs2066786
5981
T
C
560 severe
950 non-severe infections
US & Canada
0.68 odds of severe disease associated with minor allele [59]
Noa
G
A
39 severe
61 controls
Israel
2.8 odds under dominant model [60]
SCN1A
rs2298771
6323
C
T
560 severe
950 non-severe infections
US & Canada
1.47 odds of severe disease associated with minor allele [59]
Noa
A
G
39 severe
61 controls
Israel
No significant association with disease [60]
TFCP2L1
rs11122852
29,842
A
T
1330 severe
919 non-severe infections
US & Canada
3.57 odds of severe disease and 4.94 odds of Acute Flaccid Paralysis than controls [61]
No
agenotype data not available for meta-analysis

OAS1 and CCR5 have significant associations with WNV disease across multiple studies

For genes with genotype count data available for ≥2 studies, we conducted a meta-analysis of genetic association to disease severity. Meta-analysis allows recognition of well-established genetic associations and identification of redundant studies for genes with null associations. We found that SNPs in MX1, OASL, OAS1, RFC1, and CCR5 were studied by multiple research groups for an association with WNV disease (Table 2). To assess the overall association of these SNPs with WNV disease, we calculated a combined OR for each gene based on the genotype counts under four different genetic models. Of these, CCR5 and OAS1 meta-ORs were significant under a dominant model, with meta-OR of 0.83 [95% CI: 0.69–1.00] and 1.29 [1.08–1.53], respectively (Fig. 2). The CCR5 meta-OR was also significant under an allelic model with a meta-OR of 1.22 [95% CI: 1.03–1.44]. The CCR5 delta 32 deletion is associated with more severe disease while the OAS1 allele G was associated with less severe disease.

Multiple genes are associated with severity of DENV infection

Seventy-four studies have examined genetic associations with DENV disease severity and more than 30 genes have been implicated in DENV disease (Additional file 3). SNPs that were studied by only a single research group are presented in Table 3. We also include SNPs studied by multiple research groups, but for which genotype data was unavailable or the comparison groups of multiple studies could not be analyzed together.
Table 3
Genetic variation associated with DENV disease. We include in this table all variants studied by two or more research groups and variants found to have a significant association by one research group
Gene
Genetic Variation
Entrez Gene ID [31]
Major Allele
Minor Allele
Number of Cases
Number in Comparison Group
Country
Key Results
Meta-Analyzed
BAK1
rs5745568
578
G
T
509 DHF/DSS
409 DF
Thailand
1.32 (1.09–1.60) odds of severe disease associated with G allele [67]
No
CCR5
rs333
1234
Δ32 deletion
56 DF
91 controls
Australia
No significant association with disease [68]
Yes
88 DHF/DSS
335 controls
Brazil
No significant association with disease [69]
CD209/ DCSIGN
rs480803
30,835
A
G
509 DHF/DSS
409 DF
Thailand
No significant association with disease [67]
Yes
A
G
88 DHF/DSS
335 controls
Brazil
No significant association with disease [69]
A
G
112 symptomatic
104 controls
India
No significant association with disease [70]
A
G
103 symptomatic
145 asymptomatic infections
Mexico
No significant association with disease [71]
A
G
156 DF and 12 DHF
72 controls
Brazil
No significant association with disease [72]
A
G
606 symptomatic
696 controls
Thailand
5.84 (2.77–12.31) odds of DHF compared to DF and 0.204 (P = 2.0 × 10− 6) odds of symptomatic infection compared to controls [73]
A
G
286 symptomatic
236 asymptomatic infections
Brazil
No significant association with disease [74]
A
G
176 DF and 135 DH0046
120 controls
Taiwan
2.36 (1.12–4.97) odds of symptomatic infection compared to controls, 3.68 (1.67–8.09) odds of DHF compared to controls, and 2.46 (1.32–4.59) odds of DHF compared to DF [75]
CFH
rs3753394
3075
C
T
187 DHF
121 DF
Thailand
No significant association with disease [76]
Noa
   
C
T
87 DHF
34 DF
Brazil
2.53 (1.38–4.69) odds of severe disease compared to mild disease under dominant model [77]
 
CLEC5A
rs1285933
23,601
T
C
88 DHF/DSS
335 controls
Brazil
2.25 (1.07–4.87) odds of severe disease for TT compared to CC genotype [69]
No
CXCL8/ IL8
rs4973
3576
T
A
45 DHF
108 controls
India
0.43 (0.20–0.93) odds of severe disease [78]
No
DDX58
rs3205166
23,586
T
G
120 DENV positive
109 controls
India
0.66 odds of disease associated with G allele for rs3205166 [79]
No
rs11795343
rs669260
FCγRII-α
rs1801274
2212
A (H amino acid)
G (R amino acid)
103 symptomatic
145 asymptomatic infections
Mexico
0.51 (0.26–0.98) odds of symptomatic infection and 0.45 (0.21–0.96) odds of severe disease compared to controls [71]
Yes
T (H)
C (R)
89 DF and 33 DHF
107 controls
India
No significant association with disease [80]
T (H)
C (R)
68 DF, 29 DHF/DSS
42 asymptomatic infections
Cuba
10.56 (2.33–54.64) odds of DHF compared to asymptomatic disease for under dominant model [81]
T (H)
C (R)
302 DHF
238 controls
Vietnam
No significant association with disease [82]
T (H)
C (R)
40 DF, 30 DHF/DSS
40 asymptomatic infections
Pakistan
3.21 (1.29–7.97) odds of symptomatic disease, 2.82 (1.00–7.97) odds of DF, and 3.90 (1.13–13.07) odds of DHF/DSS over asymptomatic infection [83]
HPA
HPA 1a/1a
Not available
1a antigen
1b antigen
75 DHF
90 DF
India
1.93 odds (p = 0.006) of severe disease [84]
No
HPA 2a/2b
2a antigen
2b antigen
75 DHF
90 DF
India
2.8 odds (p = 0.007) of severe disease [84]
No
IFN-γ
rs2430561
3458
A
T
80 symptomatic
100 DEN-negative febrile cases and 99 healthy controls
Brazil
2.23 (p = 0.0255) odds compared to DEN-negative and 2.37 (p = 0.0165) odds compared to controls [85]
Yes
A
T
25 DHF
41 DF
Venezuela
No significant association with disease [86]
A
T
43 DHF
99 controls
Cuba
No significant association with disease [87]
IL-1B
rs16944
3553
A
G
45 DHF
108 controls
India
No significant association with disease [78]
Yes
C
T
118 symptomatic
80 controls
Brazil
No significant association with disease [88]
rs1143627
C
T
367 secondary DHF and 74 secondary DSS
313 secondary DF
Thailand
3.49 (1.36–8.95) odds of DSS compared to DHF and 2.81 (1.12–7.06) odds of DSS compared to DF under dominant models [89]
No
IL-1RA
86 base pair tandem repeat
3557
4 repeats
2 repeats
367 secondary DHF and 74 secondary DSS
313 secondary DF
Thailand
1.86 (1.05–3.26) odds of DSS compared to DHF and 1.86 (1.05–3.27) odds of DSS compared to DF for the 2/4 genotype [89]
Noa
1 repeat
2–4 repeats
280 DHF
229 controls
Vietnam
No significant association between IL-1RA repeats and DHF [82]
IL-6
rs1800795
3569
G
C
25 DHF
41 DF
Venezuela
No significant association with disease [86]
Yes
G
C
43 DHF
99 controls
Cuba
No significant association with disease [87]
G
C
118 symptomatic
80 controls
Brazil
No significant association with disease [88]
G
C
200 DF
309 controls
Brazil
0.62 (0.42–0.91) odds of disease among heterozygotes compared to homozygote wild-type [90]
IL-10
rs1800871
3586
C
T
88 DSS
335 controls
Brazil
No significant association with disease [69]
Yes
A
G
45 DHF
108 controls
India
No significant association with disease [78]
C
T
25 DHF
41 DF
Venezuela
No significant association with disease [86]
C
T
43 DHF
99 controls
Cuba
No significant association with disease [87]
C
T
200 DF
309 controls
Brazil
No significant association with disease [90]
T
C
86 DF, 182 DHF, 14 DSS
120 controls
Malaysia
No significant association with disease [91]
C
T
107 DHF
62 controls
Sri Lanka
No significant association with disease [92]
rs1800872
C
A
25 DHF
41 DF
Venezuela
No significant association with disease [86]
Yes
C
A
43 DHF
99 controls
Cuba
No significant association with disease [87]
C
A
200 DF
309 controls
Brazil
No significant association with disease [90]
A
C
86 DF, 182 DHF, 14 DSS
120 controls
Malaysia
No significant association with disease [91]
A
C
107 DHF
62 controls
Sri Lanka
No significant association with disease [92]
rs1800896
A
G
25 DHF
41 DF
Venezuela
No significant association with disease [86]
Yes
A
G
43 DHF
99 controls
Cuba
No significant association with disease [87]
A
G
200 DF
309 controls
Brazil
No significant association with disease [90]
A
G
86 DF, 182 DHF, 14 DSS
120 controls
Malaysia
No significant association with disease [91]
A
G
107 DHF
62 controls
Sri Lanka
No significant association with disease [92]
JAK1
rs11208534
3716
T
C
50 DHF
236 DF
Brazil
4.20 (1.7–10.4) odds of severe disease [74]
No
rs2780831
G
A
50 DHF
236 DF
Brazil
2.1 (1.1–4.1) odds of severe disease [74]
No
rs310196
T
G
50 DHF
236 DF
Brazil
0.4 (0.2–0.7) odds of severe disease [74]
No
MBL2
Exon 1
4153
A
O
110 symptomatic
150 controls
Brazil
No significant association with disease [93]
Yes
A
O
57 DHF
104 DF
Brazil
7.24 (1.38–38.02) odds of DHF among OO genotype compared to AA genotype [94]
MICB
rs3132468
4277
T
C
76 DSS
409 DF, 432 DHF
Thailand
1.58 (1.02–2.40) odds of DSS compared to non-DSS [95]
Yes
T
C
2008 DSS
2018 controls
Vietnam
1.34 (1.23–1.46) odds of DSS per allele [96]
T
C
3961 cases
1068 controls
Vietnam
1.42 (1.20–1.64) odds of DSS per allele [97]
PLCE1
rs3740360
51,196
A
C
2008 DSS
2018 controls
Vietnam
0.80 (0.75–0.86) odds per allele of DSS [96]
Yes
A
C
3961 cases
1068 controls
Vietnam
0.77 (0.59–0.99) odds per allele of DSS [97]
rs3765524
C
T
76 DSS
409 DF, 432 DHF
Thailand
1.49 (1.00–2.26) odds of DSS compared to non-DSS [95]
Yes
C
T
2008 DSS
2018 controls
Vietnam
0.80 (0.75–0.86) odds per allele of DSS [96]
RXRA
rs12339163
6256
G
A
60 DHF
137 asymptomatic infections and controls
Cuba
0.36 (0.17–0.77) odds of severe disease [98]
No
rs3118593
A
C
60 DHF
137 asymptomatic infections and controls
Cuba
0.44 (0.25–0.77) odds of severe disease [98]
rs4262378
G
A
60 DHF
137 asymptomatic infections and controls
Cuba
0.41 (0.24–0.72) odds of severe disease [98]
rs4424343
A
G
60 DHF
137 asymptomatic infections and controls
Cuba
0.43 [0.24–0.76] odds of severe disease [98]
rs62576287
C
A
60 DHF
137 asymptomatic infections and controls
Cuba
0.10 (0.01–0.83) odds of severe disease [98]
TAP1
amino acid 333
6890
Ile
Val
90 DF, 75 DHF, 32 DSS
100 controls
India
2.58 (p = 0.007) odds of DHF among heterozygotes compared to DF [84]
Yes
Ile
Val
107 DHF
62 controls
Sri Lanka
No significant association with disease [92]
TAP2
amino acid 379
6891
Val
Ile
107 DHF
62 controls
Sri Lanka
No significant association with disease [92]
Yes
Val
Ile
90 DF, 75 DHF, 32 DSS
100 controls
India
2.11 (p = 0.001) odds of DHF among heterozygotes [99]
TGFβ1
rs1800471
7040
G
C
25 DHF
41 DF
Venezuela
No significant association with disease [86]
 
G
C
200 DF
309 controls
Brazil
No significant association with disease [90]
rs1982073
T
C
25 DHF
41 DF
Venezuela
No significant association with disease [86]
Yes
T
C
43 DHF
99 controls
Cuba
No significant association with disease [87]
T
C
200 DF
309 controls
Brazil
No significant association with disease [90]
TIRAP
rs8177374
114,609
C
T
33 DHF
109 controls
India
2.64 (1.17–5.99) odds of severe disease among heterozygotes [100]
No
TLR3
rs3775291
7098
C
T
33 DHF
87 DF
India
0.39 (0.16–0.88) odds of severe disease associated with T allele [100]
No
TNF-α
rs361525
7124
G
A
86 DF, 182 DHF, 14 DSS
120 controls
Malaysia
4.92 (1.10–21.90) odds of DHF compared to control group for heterozygotes [91]
Yes
G
A
41 DF, 32 DHF
169 controls
Mexico
0.19 (0.02–0.78) odds of disease with A allele [101]
rs1800629
G
A
80 symptomatic
100 DEN-negative febrile cases and 99 healthy controls
Brazil
No significant association with disease [85]
Yes
G
A
25 DHF
41 DF
Venezuela
2.5 (1.47–4.13) odds of severe disease [86]
G
A
43 DHF
99 controls
Cuba
3.51 (1.77–7.00) odds of severe disease [87]
G
A
200 DF
309 controls
Brazil
No significant association with disease [90]
G
A
86 DF, 182 DHF, 14 DSS
120 controls
Malaysia
0.43 (0.22–0.84) odds of DHF compared to control for heterozygotes [91]
G
A
107 DHF
62 controls
Sri Lanka
2.53 (1.10–5.83) odds of disease for GG genotype [92]
G
A
85 DF, 29 DHF
110 controls
India
No significant association with disease [102]
G
A
19 DF, 82 DHF
106 controls
Thailand
No significant association with disease [103]
G
A
85 DF, 45 DHF
163 controls
Mexico
No significant association with disease [101]
TLR4
amino acids 299 and 399
7099
Asp299, Thr399
Gly299, Ile399
201 DHF
179 controls
Indonesia
No significant association with disease [104]
Yes
Asp299, Thr399
Gly299, Ile399
63 DF, 57 DHF/DSS
200 controls
India
2.00 (1.17–3.43) odds associated with Gly299 for DF versus controls, and 2.38 (1.16–4.85) associated with Ile399 for DF versus controls [105]
VDR
rs731236
7421
T
C
302 DHF
238 controls
Vietnam
Associated with more severe disease (p = 0.033) [82]
Yes
T
C
83 DF, 29 DHF
105 controls
India
No significant association with disease [106]
a genotype data not available for meta-analysis

Significant associations with DENV disease

Among the DENV studies, the same variant within 17 genes was studied by two or more research groups (Table 3). Four genes had significant meta-ORs (Fig. 3). For a SNP in MBL2 (exon 1), we calculated a meta-OR of 1.54 [1.02–2.31] under a dominant model and 1.65 [1.18–2.32] under an allelic model, with alleles other than the A allele being associated with more severe disease. The T allele for SNP rs2430561 in the IFN-γ gene was associated with severe disease under a recessive model with a meta-OR of 2.48 [0.30–4.71]. For a SNP located within MICB (rs3132468), we found the CC genotype had a significantly greater association with severe disease (meta-OR 2.35 [1.68–3.29]), but the heterozygote genotype showed no significant association with disease severity as compared to the TT genotype (meta-OR = 1.17 [0.86–1.59]). For this SNP, the C allele was also found to be significantly associated with disease as compared to the T allele (meta-OR = 1.35 [1.16–1.57]). For two SNPs located within the PLCE1 gene, every model tested was significant, with the most significant meta-ORs being 0.62 [0.48–0.79] for TT genotype as compared to CC genotype for rs3740360 and 0.55 [0.42–0.71] under a recessive model for rs3765524. TNF-α (rs1800629 and rs361525) was the most studied gene, but none of the models tested provided a significant meta-OR.

Quality scores

Based on the Newcastle Ottawa Scoring System, the average quality score was 5.76 (range: 3–7) for the WNV publications and 5.10 (range: 2–7) for the DENV publications (Additional file 6). We also assessed whether the study authors corrected for multiple testing, and found less than half of both WNV and DENV studies provided corrected p-values when appropriate, indicating an inflated type I error rate.

Discussion

We have examined genetic variants that show association with DENV or WNV disease severity. This analysis was undertaken to identify genetic differences that are significant drivers of susceptibility to symptomatic disease that may shed light on mechanisms of immune resistance to these viruses. Among the 87 studies examined, a wide range of genetic targets was found to be significant, with many of the genes unsurprisingly playing a key role in the immune system defense against viral infections (Additional file 7).
Despite the large number of studies, only 27 genes were studied by more than one research group for an association with either disease. Throughout these studies, several key genes rose to the forefront as the most studied and the most significant associations. Many studies focused on the HLA region of the genome, and, although inconsistencies in data presentation preclude a meta-analyze of these results, there were clear signs of the importance of this area for both diseases.
With the central role of HLA for the immune system, polymorphisms in this region have been well studied for associations with disease. The area is highly polymorphic, however, leading to difficulties for comparing the diverse range of alleles. Adding to this complexity, DENV serotypes interact differently with HLA [30]. The regions identified in this systematic review, including DRB1, DQA1, DQB1, A, B, and C, are among the most diverse regions of the HLA region [31]. A recent study examined some of these regions by supertype, and found the B44 supertype could be protective against DHF during secondary infections and that the A02 and A01/03 supertypes could be associated with more severe disease [32].
KIR genes, which are expressed on the surface of natural killer cells, also have wide genetic variability as noted with HLA genes [33]. While several KIR alleles were studied in DENV-infected populations, only one publication to date has examined KIR genotypes in West Nile virus-infected individuals, and this study had a sample size of four [34]. The results suggested a possible association; this, in conjunction with the results of the DENV research in this area and the genes’ highly polymorphic nature, could be an area that should be explored further. Infection with WNV has been shown to lead to diversification of KIR receptor expression [35]. In addition to the research outlined above, researchers have examined the association of KIR genotypes with DENV infection in vitro. Within the in vitro research, the timing of natural killer cell activation has been linked to disease severity and interactions between KIR and HLA have been suggested [3638].
Another key non-HLA gene identified to be associated with WNV disease was OASL, which codes for an enzyme that is induced by type 1 interferon and viruses [39]. OASL was first identified to have a potentially critical role in WNV disease pathogenesis in 2002, when researchers found that mice with a truncated form of the gene were more susceptible to disease [40]. Elevated activity of the OAS genes has also been associated with more severe DENV infection in vitro [41]. This data and the significance of variation within the OAS genes for WNV outcomes highlight the importance of the interferon pathways in response to flavivirus infections and suggest a need for further in depth examination the association of genetic variability within OAS and DENV severity.
CCR5Δ32 was the only gene studied by two or more research groups for each disease. CCR5 was first identified as a co-receptor for HIV in 1996, and CCR5 deficiency, or a homozygous genotype of CCR5Δ32, was found to be protective against HIV infection [4245]. In West Nile, CCR5 deficiency is not associated with incidence of infection, but is associated with severity of disease for infected individuals [46]. Subsequent research showed that CCR5 specifically plays a role in the ability of cortical neurons to combat West Nile virus infection of the brain [47]. In DENV, CCR5 deficiency has been linked with increased viral load and disease severity [48]. The study also found that the CCR5 receptor in macrophages is necessary for replication of DENV serotype 2, an early step in the infection process [49]. Given the similarities of these flaviviral diseases and the significant association of CCR5, the only gene looked at by research groups for both diseases, further research could be beneficial to further understanding the role of genetic variation in the development of severe flavivviral disease [50].
When we meta-analyzed the DENV studies, we found significant associations between DENV disease and genetic variation in MBL2, PLCE1, IFN-γ, and MICB. The role of many of these genes in disease pathogenesis has been characterized through in vivo and in vitro studies. MBL2, the mannose-binding lectin 2 gene, encodes a protein with a role in innate immunity and complement pathway, while PLCE1 encodes an enzyme critical to the generation of the inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG) messengers [51]. MICB and IFN-y are both critical in the immune response, and thus variations within these genes could have strong effects on the initial response to the viral infection and the subsequent disease pathogenesis [51].
Our study is limited by several factors, most notably by the available literature. To ensure we found as many papers as possible, we constructed a search strategy that involved multiple databases, used both subject headings and text words, was not limited to English articles, and included an ancestry search [52]. Despite our focus on significant results and genes studied by at least two research groups, the wide heterogeneity among the populations studied limited our ability to interpret the meta-analyzed results. Lack of diversity in genetic studies is well-documented [53], and the absence of certain affected populations, particularly in Africa, among the identified studies further demonstrates this unmet research need [54]. The diversity of results among studies that examined the same SNP could be due to population heterogeneity, as well as to differences in study approach, including selection of control and comparison groups. Additionally, previous exposure history, DENV serotype, and WNV or DENV genotype are all factors that can affect disease severity, but were not accounted for in the included studies [4]. The number and type of genes examined varied greatly between studies, and we were limited by what genes researchers chose to sequence and include in publications. The unavailability of comparable genotype data and the incomparability of research groups across some studies preclude a more in depth analysis at present.

Conclusions

The genes found to be significantly associated with WNV or DENV disease pathogenesis varied in function, with most being linked to the immune response. As the regions of the world affected by WNV, DENV, and related viruses such as Zika, continue to expand due in part to climate change, an improved understanding of the association between genetic variation and disease severity will be valuable for all potentially affected populations [5558]. Based on the growing incidence of these diseases, the paucity of consistency in the associations found, and the limited overlap in genetic targets studied to date, there is need for continued and deeper studies examining the role of genetic factors in WNV and DENV disease severity. In addition to conducting new studies such as whole-exome sequencing within larger population samples, further analyses could be conducted of existing data, to glean novel findings such as gene-gene or gene-environment interactions, rare and low frequency variants, and pathways of significant determinants of anti-viral resistance.

Acknowledgements

The authors are grateful to many colleagues for valuable advice, and particularly wish to thank Ms. Xiaomei Wang for technical input, Ms. Kate Nyhan, MLS, (Yale University Cushing/Whitney Medical Library) for guidance in the development of the search strategy, and Dr. Marina Antillón for translating Spanish-language articles during the full text review.

Funding

MEC & RRM: AI 089992; SC: Self and Family Management T32 NR008346. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.
Not applicable. Data sets were extracted without personal identifiers and organized into literature tables.
Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Anhänge

Additional files

Literatur
1.
Zurück zum Zitat Papa A, Karabaxoglou D, Kansouzidou A. Acute West Nile virus neuroinvasive infections: cross-reactivity with dengue virus and tick-borne encephalitis virus. J Med Virol. 2011;83(10):1861–5.CrossRefPubMed Papa A, Karabaxoglou D, Kansouzidou A. Acute West Nile virus neuroinvasive infections: cross-reactivity with dengue virus and tick-borne encephalitis virus. J Med Virol. 2011;83(10):1861–5.CrossRefPubMed
2.
Zurück zum Zitat Hua RH, Chen NS, Qin CF, Deng YQ, Ge JY, Wang XJ, Qiao ZJ, Chen WY, Wen ZY, Liu WX, et al. Identification and characterization of a virus-specific continuous B-cell epitope on the PrM/M protein of Japanese encephalitis virus: potential application in the detection of antibodies to distinguish Japanese encephalitis virus infection from West Nile virus and dengue virus infections. Virol J. 2010;7:249.CrossRefPubMedPubMedCentral Hua RH, Chen NS, Qin CF, Deng YQ, Ge JY, Wang XJ, Qiao ZJ, Chen WY, Wen ZY, Liu WX, et al. Identification and characterization of a virus-specific continuous B-cell epitope on the PrM/M protein of Japanese encephalitis virus: potential application in the detection of antibodies to distinguish Japanese encephalitis virus infection from West Nile virus and dengue virus infections. Virol J. 2010;7:249.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Daep CA, Munoz-Jordan JL, Eugenin EA. Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus. J Neuro-Oncol. 2014;20(6):539–60. Daep CA, Munoz-Jordan JL, Eugenin EA. Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus. J Neuro-Oncol. 2014;20(6):539–60.
4.
Zurück zum Zitat Gubler DJ. The continuing spread of West Nile virus in the western hemisphere. Clin Infect Dis. 2007;45(8):1039–46.CrossRefPubMed Gubler DJ. The continuing spread of West Nile virus in the western hemisphere. Clin Infect Dis. 2007;45(8):1039–46.CrossRefPubMed
7.
Zurück zum Zitat Coffey LL, Mertens E, Brehin AC, Fernandez-Garcia MD, Amara A, Despres P, Sakuntabhai A. Human genetic determinants of dengue virus susceptibility. Microbes Infect. 2009;11(2):143–56.CrossRefPubMed Coffey LL, Mertens E, Brehin AC, Fernandez-Garcia MD, Amara A, Despres P, Sakuntabhai A. Human genetic determinants of dengue virus susceptibility. Microbes Infect. 2009;11(2):143–56.CrossRefPubMed
9.
Zurück zum Zitat Montgomery RR, Murray KO. Risk factors for West Nile virus infection and disease in populations and individuals. Expert Rev Anti-Infect Ther. 2015;13(3):317–25.CrossRefPubMedPubMedCentral Montgomery RR, Murray KO. Risk factors for West Nile virus infection and disease in populations and individuals. Expert Rev Anti-Infect Ther. 2015;13(3):317–25.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Whitehorn J, Hubbard S, Anders KL, Quyen NTH, Simmons C. Dengue pathogenesis: host factors. Dengue and Dengue Hemorrhagic Fever, 2nd Edition. 2014:214–28. Whitehorn J, Hubbard S, Anders KL, Quyen NTH, Simmons C. Dengue pathogenesis: host factors. Dengue and Dengue Hemorrhagic Fever, 2nd Edition. 2014:214–28.
11.
Zurück zum Zitat James EA, Gates TJ, LaFond RE, Yamamoto S, Ni C, Mai D, Gersuk VH, O'Brien K, Nguyen QA, Zeitner B, et al. Neuroinvasive West Nile infection elicits elevated and atypically polarized T cell responses that promote a pathogenic outcome. PLoS Pathog. 2016;12(1):e1005375.CrossRefPubMedPubMedCentral James EA, Gates TJ, LaFond RE, Yamamoto S, Ni C, Mai D, Gersuk VH, O'Brien K, Nguyen QA, Zeitner B, et al. Neuroinvasive West Nile infection elicits elevated and atypically polarized T cell responses that promote a pathogenic outcome. PLoS Pathog. 2016;12(1):e1005375.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Qian F, Thakar J, Yuan X, Nolan M, Murray KO, Lee WT, Wong SJ, Meng H, Fikrig E, Kleinstein SH, et al. Immune markers associated with host susceptibility to infection with West Nile virus. Viral Immunol. 2014;27(2):39–47.CrossRefPubMedPubMedCentral Qian F, Thakar J, Yuan X, Nolan M, Murray KO, Lee WT, Wong SJ, Meng H, Fikrig E, Kleinstein SH, et al. Immune markers associated with host susceptibility to infection with West Nile virus. Viral Immunol. 2014;27(2):39–47.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Cahill ME, Yao Y, Nock D, Armstrong PM, Andreadis TG, Diuk-Wasser MA, Montgomery RR. West Nile Virus Seroprevalence, Connecticut, USA, 2000-2014. Emerg Infect Dis. 2017;23(4):708–10.CrossRefPubMedPubMedCentral Cahill ME, Yao Y, Nock D, Armstrong PM, Andreadis TG, Diuk-Wasser MA, Montgomery RR. West Nile Virus Seroprevalence, Connecticut, USA, 2000-2014. Emerg Infect Dis. 2017;23(4):708–10.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Krishnan MN, Sukumaran B, Pal U, Agaisse H, Murray JL, Hodge TW, Fikrig E. Rab 5 is required for the cellular entry of dengue and West Nile viruses. J Virol. 2007;81(9):4881–5.CrossRefPubMedPubMedCentral Krishnan MN, Sukumaran B, Pal U, Agaisse H, Murray JL, Hodge TW, Fikrig E. Rab 5 is required for the cellular entry of dengue and West Nile viruses. J Virol. 2007;81(9):4881–5.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Campos RK, Wong B, Xie XP, Lu YF, Shi PY, Pompon J, Garcia-Blanco MA, Bradrick SS. RPLP1 and RPLP2 are essential Flavivirus host factors that promote early viral protein accumulation. J Virol. 2017;91(4) Campos RK, Wong B, Xie XP, Lu YF, Shi PY, Pompon J, Garcia-Blanco MA, Bradrick SS. RPLP1 and RPLP2 are essential Flavivirus host factors that promote early viral protein accumulation. J Virol. 2017;91(4)
18.
Zurück zum Zitat Chaturvedi UC, Agarwal R, Elbishbishi EA, Mustafa AS. Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis. FEMS Immunol Med Microbiol. 2000;28(3):183–8.CrossRefPubMed Chaturvedi UC, Agarwal R, Elbishbishi EA, Mustafa AS. Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis. FEMS Immunol Med Microbiol. 2000;28(3):183–8.CrossRefPubMed
19.
Zurück zum Zitat Kumar M, Verma S, Nerurkar VR. Pro-inflammatory cytokines derived from West Nile virus (WNV)-infected SK-N-SH cells mediate neuroinflammatory markers and neuronal death. J Neuroinflammation. 2010;7:73.CrossRefPubMedPubMedCentral Kumar M, Verma S, Nerurkar VR. Pro-inflammatory cytokines derived from West Nile virus (WNV)-infected SK-N-SH cells mediate neuroinflammatory markers and neuronal death. J Neuroinflammation. 2010;7:73.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Rossini G, Landini MP, Gelsomino F, Sambri V, Varani S. Innate host responses to West Nile virus: implications for central nervous system immunopathology. World J Virol. 2013;2(2):49–56.CrossRefPubMedPubMedCentral Rossini G, Landini MP, Gelsomino F, Sambri V, Varani S. Innate host responses to West Nile virus: implications for central nervous system immunopathology. World J Virol. 2013;2(2):49–56.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med. 2004;10(12):S98–S109.CrossRefPubMed Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med. 2004;10(12):S98–S109.CrossRefPubMed
23.
Zurück zum Zitat Hotez PJ, Murray KO. Dengue, West Nile virus, chikungunya, Zika - and now Mayaro? PLoS Negl Trop Dis. 2017;11(8): e0005462. Hotez PJ, Murray KO. Dengue, West Nile virus, chikungunya, Zika - and now Mayaro? PLoS Negl Trop Dis. 2017;11(8): e0005462.
24.
25.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.CrossRefPubMedPubMedCentral Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Tomas J. Aragon MPF, Daniel Wollschlaeger, Adam Omidpanah: epitools: Epidemiology Tools. In.; 2017. Tomas J. Aragon MPF, Daniel Wollschlaeger, Adam Omidpanah: epitools: Epidemiology Tools. In.; 2017.
28.
Zurück zum Zitat Review Manager (RevMan). In., 5.3 EDN Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014. Review Manager (RevMan). In., 5.3 EDN Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
29.
Zurück zum Zitat Wells G, Shea B, O’connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In.; 2000. Wells G, Shea B, O’connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In.; 2000.
30.
Zurück zum Zitat Gan CS, Yusof R, Othman S. Different serotypes of dengue viruses differently regulate the expression of the host cell antigen processing machinery. Acta Trop. 2015;149:8–14.CrossRefPubMed Gan CS, Yusof R, Othman S. Different serotypes of dengue viruses differently regulate the expression of the host cell antigen processing machinery. Acta Trop. 2015;149:8–14.CrossRefPubMed
31.
Zurück zum Zitat Shiina T, Hosomichi K, Inoko H, Kulski JK. The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet. 2009;54(1):15–39.CrossRefPubMed Shiina T, Hosomichi K, Inoko H, Kulski JK. The HLA genomic loci map: expression, interaction, diversity and disease. J Hum Genet. 2009;54(1):15–39.CrossRefPubMed
32.
Zurück zum Zitat Vejbaesya S, Thongpradit R, Kalayanarooj S, Luangtrakool K, Luangtrakool P, Gibbons RV, Srinak D, Ngammthaworn S, Apisawes K, Yoon IK, et al. HLA class I Supertype associations with clinical outcome of secondary dengue virus infections in ethnic Thais. J Infect Dis. 2015;212(6):939–47.CrossRefPubMedPubMedCentral Vejbaesya S, Thongpradit R, Kalayanarooj S, Luangtrakool K, Luangtrakool P, Gibbons RV, Srinak D, Ngammthaworn S, Apisawes K, Yoon IK, et al. HLA class I Supertype associations with clinical outcome of secondary dengue virus infections in ethnic Thais. J Infect Dis. 2015;212(6):939–47.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Uhrberg M. The KIR gene family: life in the fast lane of evolution. Eur J Immunol. 2005;35(1):10–5.CrossRefPubMed Uhrberg M. The KIR gene family: life in the fast lane of evolution. Eur J Immunol. 2005;35(1):10–5.CrossRefPubMed
34.
Zurück zum Zitat Spiroski M, Milenkovic Z, Petlichkovski A, Ivanovski L, Topuzovska IK, Djulejic E. Killer cell immunoglobulin-like receptor genes in four human West Nile virus infections reported 2011 in the republic of Macedonia. Hum Immunol. 2013;74(3):389–94.CrossRefPubMed Spiroski M, Milenkovic Z, Petlichkovski A, Ivanovski L, Topuzovska IK, Djulejic E. Killer cell immunoglobulin-like receptor genes in four human West Nile virus infections reported 2011 in the republic of Macedonia. Hum Immunol. 2013;74(3):389–94.CrossRefPubMed
35.
Zurück zum Zitat Strauss-Albee DM, Fukuyama J, Liang EC, Yao Y, Jarrell JA, Drake AL, Kinuthia J, Montgomery RR, John-Stewart G, Holmes S, et al. Human NK cell repertoire diversity reflects immune experience and correlates with viral susceptibility. Sci Transl Med. 2015;7(297):297ra115.CrossRefPubMedPubMedCentral Strauss-Albee DM, Fukuyama J, Liang EC, Yao Y, Jarrell JA, Drake AL, Kinuthia J, Montgomery RR, John-Stewart G, Holmes S, et al. Human NK cell repertoire diversity reflects immune experience and correlates with viral susceptibility. Sci Transl Med. 2015;7(297):297ra115.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Azeredo EL, De Oliveira-Pinto LM, Zagne SM, Cerqueira DI, Nogueira RM, Kubelka CF. NK cells, displaying early activation, cytotoxicity and adhesion molecules, are associated with mild dengue disease. Clin Exp Immunol. 2006;143(2):345–56.CrossRefPubMedPubMedCentral Azeredo EL, De Oliveira-Pinto LM, Zagne SM, Cerqueira DI, Nogueira RM, Kubelka CF. NK cells, displaying early activation, cytotoxicity and adhesion molecules, are associated with mild dengue disease. Clin Exp Immunol. 2006;143(2):345–56.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Townsley E, O'Connor G, Cosgrove C, Woda M, Co M, Thomas SJ, Kalayanarooj S, Yoon IK, Nisalak A, Srikiatkhachorn A, et al. Interaction of a dengue virus NS1-derived peptide with the inhibitory receptor KIR3DL1 on natural killer cells. Clin Exp Immunol. 2016;183(3):419–30.CrossRefPubMed Townsley E, O'Connor G, Cosgrove C, Woda M, Co M, Thomas SJ, Kalayanarooj S, Yoon IK, Nisalak A, Srikiatkhachorn A, et al. Interaction of a dengue virus NS1-derived peptide with the inhibitory receptor KIR3DL1 on natural killer cells. Clin Exp Immunol. 2016;183(3):419–30.CrossRefPubMed
38.
Zurück zum Zitat Yao Y, Strauss-Albee DM, Zhou JQ, Malawista A, Garcia MN, Murray KO, Blish CA, Montgomery RR. The natural killer cell response to West Nile virus in young and old individuals with or without a prior history of infection. PLoS One. 2017;12(2):e0172625.CrossRefPubMedPubMedCentral Yao Y, Strauss-Albee DM, Zhou JQ, Malawista A, Garcia MN, Murray KO, Blish CA, Montgomery RR. The natural killer cell response to West Nile virus in young and old individuals with or without a prior history of infection. PLoS One. 2017;12(2):e0172625.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Mashimo T, Lucas M, Simon-Chazottes D, Frenkiel MP, Montagutelli X, Ceccaldi PE, Deubel V, Guenet JL, Despres P. A nonsense mutation in the gene encoding 2′-5′-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. Proc Natl Acad Sci U S A. 2002;99(17):11311–6.CrossRefPubMedPubMedCentral Mashimo T, Lucas M, Simon-Chazottes D, Frenkiel MP, Montagutelli X, Ceccaldi PE, Deubel V, Guenet JL, Despres P. A nonsense mutation in the gene encoding 2′-5′-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. Proc Natl Acad Sci U S A. 2002;99(17):11311–6.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Simon-Loriere E, Lin RJ, Kalayanarooj SM, Chuansumrit A, Casademont I, Lin SY, Yu HP, Lert-Itthiporn W, Chaiyaratana W, Tangthawornchaikul N, et al. High anti-dengue virus activity of the OAS gene family is associated with increased severity of dengue. J Infect Dis. 2015;212(12):2011–20.CrossRefPubMed Simon-Loriere E, Lin RJ, Kalayanarooj SM, Chuansumrit A, Casademont I, Lin SY, Yu HP, Lert-Itthiporn W, Chaiyaratana W, Tangthawornchaikul N, et al. High anti-dengue virus activity of the OAS gene family is associated with increased severity of dengue. J Infect Dis. 2015;212(12):2011–20.CrossRefPubMed
42.
Zurück zum Zitat Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996;272(5270):1955–8.CrossRefPubMed Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996;272(5270):1955–8.CrossRefPubMed
43.
Zurück zum Zitat Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381(6584):661–6.CrossRefPubMed Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 1996;381(6584):661–6.CrossRefPubMed
44.
Zurück zum Zitat Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381(6584):667–73.CrossRefPubMed Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature. 1996;381(6584):667–73.CrossRefPubMed
45.
Zurück zum Zitat Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86(3):367–77.CrossRefPubMed Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86(3):367–77.CrossRefPubMed
46.
Zurück zum Zitat Lim JK, McDermott DH, Lisco A, Foster GA, Krysztof D, Follmann D, Stramer SL, Murphy PM. CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J Infect Dis. 2010;201(2):178–85.CrossRefPubMedPubMedCentral Lim JK, McDermott DH, Lisco A, Foster GA, Krysztof D, Follmann D, Stramer SL, Murphy PM. CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J Infect Dis. 2010;201(2):178–85.CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Durrant DM, Daniels BP, Pasieka T, Dorsey D, Klein RS. CCR5 limits cortical viral loads during West Nile virus infection of the central nervous system. J Neuroinflammation. 2015;12:233.CrossRefPubMedPubMedCentral Durrant DM, Daniels BP, Pasieka T, Dorsey D, Klein RS. CCR5 limits cortical viral loads during West Nile virus infection of the central nervous system. J Neuroinflammation. 2015;12:233.CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Marques RE, Guabiraba R, Del Sarto JL, Rocha RF, Queiroz AL, Cisalpino D, Marques PE, Pacca CC, Fagundes CT, Menezes GB, et al. Dengue virus requires the CC-chemokine receptor CCR5 for replication and infection development. Immunology. 2015;145(4):583–96.CrossRefPubMedPubMedCentral Marques RE, Guabiraba R, Del Sarto JL, Rocha RF, Queiroz AL, Cisalpino D, Marques PE, Pacca CC, Fagundes CT, Menezes GB, et al. Dengue virus requires the CC-chemokine receptor CCR5 for replication and infection development. Immunology. 2015;145(4):583–96.CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Chen YC, Wang SY. Activation of terminally differentiated human monocytes/macrophages by dengue virus: productive infection, hierarchical production of innate cytokines and chemokines, and the synergistic effect of lipopolysaccharide. J Virol. 2002;76(19):9877–87.CrossRefPubMedPubMedCentral Chen YC, Wang SY. Activation of terminally differentiated human monocytes/macrophages by dengue virus: productive infection, hierarchical production of innate cytokines and chemokines, and the synergistic effect of lipopolysaccharide. J Virol. 2002;76(19):9877–87.CrossRefPubMedPubMedCentral
50.
Zurück zum Zitat Loeb M. Genetic susceptibility to West Nile virus and dengue. Public Health Genomics. 2013;16(1–2):4–8.CrossRefPubMed Loeb M. Genetic susceptibility to West Nile virus and dengue. Public Health Genomics. 2013;16(1–2):4–8.CrossRefPubMed
56.
Zurück zum Zitat Paz S. Climate change impacts on West Nile virus transmission in a global context. Philos Trans R Soc Lond Ser B Biol Sci. 2015;370(1665) Paz S. Climate change impacts on West Nile virus transmission in a global context. Philos Trans R Soc Lond Ser B Biol Sci. 2015;370(1665)
57.
58.
Zurück zum Zitat Lessler J, Chaisson LH, Kucirka LM, Bi Q, Grantz K, Salje H, Carcelen AC, Ott CT, Sheffield JS, Ferguson NM, et al. Assessing the global threat from Zika virus. Science. 2016;353(6300):aaf8160.CrossRefPubMedPubMedCentral Lessler J, Chaisson LH, Kucirka LM, Bi Q, Grantz K, Salje H, Carcelen AC, Ott CT, Sheffield JS, Ferguson NM, et al. Assessing the global threat from Zika virus. Science. 2016;353(6300):aaf8160.CrossRefPubMedPubMedCentral
59.
Zurück zum Zitat Loeb M, Eskandarian S, Rupp M, Fishman N, Gasink L, Patterson J, Bramson J, Hudson TJ, Lemire M. Genetic variants and susceptibility to neurological complications following West Nile virus infection. J Infect Dis. 2011;204(7):1031–7.CrossRefPubMedPubMedCentral Loeb M, Eskandarian S, Rupp M, Fishman N, Gasink L, Patterson J, Bramson J, Hudson TJ, Lemire M. Genetic variants and susceptibility to neurological complications following West Nile virus infection. J Infect Dis. 2011;204(7):1031–7.CrossRefPubMedPubMedCentral
60.
Zurück zum Zitat Danial-Farran N, Eghbaria S, Schwartz N, Kra-Oz Z, Bisharat N. Genetic variants associated with susceptibility of Ashkenazi Jews to West Nile virus infection. Epidemiology & Infection. 2015;143(4):857–63.CrossRef Danial-Farran N, Eghbaria S, Schwartz N, Kra-Oz Z, Bisharat N. Genetic variants associated with susceptibility of Ashkenazi Jews to West Nile virus infection. Epidemiology & Infection. 2015;143(4):857–63.CrossRef
61.
Zurück zum Zitat Long D, Deng X, Singh P, Loeb M, Lauring AS, Seielstad M. Identification of genetic variants associated with susceptibility to West Nile virus neuroinvasive disease. Genes & Immunity. 2016;17(5):298–304.CrossRef Long D, Deng X, Singh P, Loeb M, Lauring AS, Seielstad M. Identification of genetic variants associated with susceptibility to West Nile virus neuroinvasive disease. Genes & Immunity. 2016;17(5):298–304.CrossRef
62.
Zurück zum Zitat Bigham AW, Buckingham KJ, Husain S, Emond MJ, Bofferding KM, Gildersleeve H, Rutherford A, Astakhova NM, Perelygin AA, Busch MP et al: Host genetic risk factors for West Nile virus infection and disease progression. PLoS One 2011, 6 (9) (no pagination)(e24745). Bigham AW, Buckingham KJ, Husain S, Emond MJ, Bofferding KM, Gildersleeve H, Rutherford A, Astakhova NM, Perelygin AA, Busch MP et al: Host genetic risk factors for West Nile virus infection and disease progression. PLoS One 2011, 6 (9) (no pagination)(e24745).
63.
Zurück zum Zitat Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, Pape J, Cheshier RC, Murphy PM. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med. 2006;203(1):35–40.CrossRefPubMedPubMedCentral Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, Pape J, Cheshier RC, Murphy PM. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med. 2006;203(1):35–40.CrossRefPubMedPubMedCentral
64.
Zurück zum Zitat Das R, Loughran K, Murchison C, Qian F, Leng L, Song Y, Montgomery RR, Loeb M, Bucala R. Association between high expression macrophage migration inhibitory factor (MIF) alleles and West Nile virus encephalitis. Cytokine. 2016;78:51–4.CrossRefPubMed Das R, Loughran K, Murchison C, Qian F, Leng L, Song Y, Montgomery RR, Loeb M, Bucala R. Association between high expression macrophage migration inhibitory factor (MIF) alleles and West Nile virus encephalitis. Cytokine. 2016;78:51–4.CrossRefPubMed
65.
Zurück zum Zitat Yakub I, Lillibridge KM, Moran A, Gonzalez OY, Belmont J, Gibbs RA, Tweardy DJ. Single nucleotide polymorphisms in genes for 2′-5′-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection. J Infect Dis. 2005;192(10):1741–8.CrossRefPubMed Yakub I, Lillibridge KM, Moran A, Gonzalez OY, Belmont J, Gibbs RA, Tweardy DJ. Single nucleotide polymorphisms in genes for 2′-5′-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection. J Infect Dis. 2005;192(10):1741–8.CrossRefPubMed
66.
Zurück zum Zitat Lim JK, Lisco A, McDermott DH, Huynh L, Ward JM, Johnson B, Johnson H, Pape J, Foster GA, Krysztof D, et al. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog. 2009;5(2):e1000321.CrossRefPubMedPubMedCentral Lim JK, Lisco A, McDermott DH, Huynh L, Ward JM, Johnson B, Johnson H, Pape J, Foster GA, Krysztof D, et al. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog. 2009;5(2):e1000321.CrossRefPubMedPubMedCentral
67.
Zurück zum Zitat Dang TN, Naka I, Sa-Ngasang A, Anantapreecha S, Wichukchinda N, Sawanpanyalert P, Patarapotikul J, Tsuchiya N, Ohashi J. Association of BAK1 single nucleotide polymorphism with a risk for dengue hemorrhagic fever. BMC Medical Genetics. 2016;17(1):43.CrossRefPubMedPubMedCentral Dang TN, Naka I, Sa-Ngasang A, Anantapreecha S, Wichukchinda N, Sawanpanyalert P, Patarapotikul J, Tsuchiya N, Ohashi J. Association of BAK1 single nucleotide polymorphism with a risk for dengue hemorrhagic fever. BMC Medical Genetics. 2016;17(1):43.CrossRefPubMedPubMedCentral
68.
Zurück zum Zitat Brestovac B, Halicki LA, Harris RP, Sampson I, Speers DJ, Mamotte C, Williams D. Primary acute dengue and the deletion in chemokine receptor 5 (CCR5DELTA32). Microbes & Infection. 2014;16(6):518–21.CrossRef Brestovac B, Halicki LA, Harris RP, Sampson I, Speers DJ, Mamotte C, Williams D. Primary acute dengue and the deletion in chemokine receptor 5 (CCR5DELTA32). Microbes & Infection. 2014;16(6):518–21.CrossRef
69.
Zurück zum Zitat Xavier-Carvalho C, Gibson G, Brasil P, Ferreira RX, de Souza Santos R, Goncalves Cruz O, de Oliveira SA, de Sa Carvalho M, Pacheco AG, Kubelka CF, et al. Single nucleotide polymorphisms in candidate genes and dengue severity in children: a case-control, functional and meta-analysis study. Infection, Genetics & Evolution. 2013;20:197–205.CrossRef Xavier-Carvalho C, Gibson G, Brasil P, Ferreira RX, de Souza Santos R, Goncalves Cruz O, de Oliveira SA, de Sa Carvalho M, Pacheco AG, Kubelka CF, et al. Single nucleotide polymorphisms in candidate genes and dengue severity in children: a case-control, functional and meta-analysis study. Infection, Genetics & Evolution. 2013;20:197–205.CrossRef
70.
Zurück zum Zitat Alagarasu K, Damle IM, Bachal RV, Mulay AP, Shah PS, Dayaraj C. Association of promoter region polymorphisms of CD209 gene with clinical outcomes of dengue virus infection in western India. Infection, Genetics & Evolution. 2013;17:239–42.CrossRef Alagarasu K, Damle IM, Bachal RV, Mulay AP, Shah PS, Dayaraj C. Association of promoter region polymorphisms of CD209 gene with clinical outcomes of dengue virus infection in western India. Infection, Genetics & Evolution. 2013;17:239–42.CrossRef
71.
Zurück zum Zitat Noecker CA, Amaya-Larios IY, Galeana-Hernandez M, Ramos-Castaneda J, Martinez-Vega RA. Contrasting associations of polymorphisms in FcgammaRIIa and DC-SIGN with the clinical presentation of dengue infection in a Mexican population. Acta Trop. 2014;138:15–22.CrossRefPubMed Noecker CA, Amaya-Larios IY, Galeana-Hernandez M, Ramos-Castaneda J, Martinez-Vega RA. Contrasting associations of polymorphisms in FcgammaRIIa and DC-SIGN with the clinical presentation of dengue infection in a Mexican population. Acta Trop. 2014;138:15–22.CrossRefPubMed
72.
Zurück zum Zitat Oliveira LF, Lima CP, Azevedo Rdo S, Mendonca DS, Rodrigues SG, Carvalho VL, Pinto EV, Maia AL, Maia MH, Vasconcelos JM, et al. Polymorphism of DC-SIGN (CD209) promoter in association with clinical symptoms of dengue fever. Viral Immunol. 2014;27(5):245–9.CrossRefPubMed Oliveira LF, Lima CP, Azevedo Rdo S, Mendonca DS, Rodrigues SG, Carvalho VL, Pinto EV, Maia AL, Maia MH, Vasconcelos JM, et al. Polymorphism of DC-SIGN (CD209) promoter in association with clinical symptoms of dengue fever. Viral Immunol. 2014;27(5):245–9.CrossRefPubMed
73.
Zurück zum Zitat Sakuntabhai A, Turbpaiboon C, Casademont I, Chuansumrit A, Lowhnoo T, Kajaste-Rudnitski A, Kalayanarooj SM, Tangnararatchakit K, Tangthawornchaikul N, Vasanawathana S, et al. A variant in the CD209 promoter is associated with severity of dengue disease. Nat Genet. 2005;37(5):507–13.CrossRefPubMed Sakuntabhai A, Turbpaiboon C, Casademont I, Chuansumrit A, Lowhnoo T, Kajaste-Rudnitski A, Kalayanarooj SM, Tangnararatchakit K, Tangthawornchaikul N, Vasanawathana S, et al. A variant in the CD209 promoter is associated with severity of dengue disease. Nat Genet. 2005;37(5):507–13.CrossRefPubMed
74.
Zurück zum Zitat Silva LK, Blanton RE, Parrado AR, Melo PS, Morato VG, Reis EA, Dias JP, Castro JM, Vasconcelos PF, Goddard KA, et al. Dengue hemorrhagic fever is associated with polymorphisms in JAK1. Eur J Hum Genet. 2010;18(11):1221–7.CrossRefPubMedPubMedCentral Silva LK, Blanton RE, Parrado AR, Melo PS, Morato VG, Reis EA, Dias JP, Castro JM, Vasconcelos PF, Goddard KA, et al. Dengue hemorrhagic fever is associated with polymorphisms in JAK1. Eur J Hum Genet. 2010;18(11):1221–7.CrossRefPubMedPubMedCentral
75.
Zurück zum Zitat Wang L, Chen RF, Liu JW, Lee IK, Lee CP, Kuo HC, Huang SK, Yang KD. DC-SIGN (CD209) promoter −336 a/G polymorphism is associated with dengue hemorrhagic fever and correlated to DC-SIGN expression and immune augmentation. PLoS Neglected Tropical Diseases [electronic resource]. 2011;5(1):e934.CrossRef Wang L, Chen RF, Liu JW, Lee IK, Lee CP, Kuo HC, Huang SK, Yang KD. DC-SIGN (CD209) promoter −336 a/G polymorphism is associated with dengue hemorrhagic fever and correlated to DC-SIGN expression and immune augmentation. PLoS Neglected Tropical Diseases [electronic resource]. 2011;5(1):e934.CrossRef
76.
Zurück zum Zitat Kraivong R, Vasanawathana S, Limpitikul W, Malasit P, Tangthawornchaikul N, Botto M, Screaton GR, Mongkolsapaya J, Pickering MC. Complement alternative pathway genetic variation and dengue infection in the Thai population. Clinical & Experimental Immunology. 2013;174(2):326–34. Kraivong R, Vasanawathana S, Limpitikul W, Malasit P, Tangthawornchaikul N, Botto M, Screaton GR, Mongkolsapaya J, Pickering MC. Complement alternative pathway genetic variation and dengue infection in the Thai population. Clinical & Experimental Immunology. 2013;174(2):326–34.
77.
Zurück zum Zitat Pastor AF, Rodrigues Moura L, Neto JW, Nascimento EJ, Calzavara-Silva CE, Gomes AL, Silva AM, Cordeiro MT, Braga-Neto U, Crovella S, et al. Complement factor H gene (CFH) polymorphisms C-257T, G257A and haplotypes are associated with protection against severe dengue phenotype, possible related with high CFH expression. Hum Immunol. 2013;74(9):1225–30.CrossRefPubMedPubMedCentral Pastor AF, Rodrigues Moura L, Neto JW, Nascimento EJ, Calzavara-Silva CE, Gomes AL, Silva AM, Cordeiro MT, Braga-Neto U, Crovella S, et al. Complement factor H gene (CFH) polymorphisms C-257T, G257A and haplotypes are associated with protection against severe dengue phenotype, possible related with high CFH expression. Hum Immunol. 2013;74(9):1225–30.CrossRefPubMedPubMedCentral
78.
Zurück zum Zitat Alagarasu K, Bachal RV, Tillu H, Mulay AP, Kakade MB, Shah PS, Cecilia D. Association of combinations of interleukin-10 and pro-inflammatory cytokine gene polymorphisms with dengue hemorrhagic fever. Cytokine. 2015;74(1):130–6.CrossRefPubMed Alagarasu K, Bachal RV, Tillu H, Mulay AP, Kakade MB, Shah PS, Cecilia D. Association of combinations of interleukin-10 and pro-inflammatory cytokine gene polymorphisms with dengue hemorrhagic fever. Cytokine. 2015;74(1):130–6.CrossRefPubMed
79.
Zurück zum Zitat Alagarasu K, Memane RS, Shah PS. Polymorphisms in the retinoic acid-1 like-receptor family of genes and their association with clinical outcome of dengue virus infection. Arch Virol. 2015;160(6):1555–60.CrossRefPubMed Alagarasu K, Memane RS, Shah PS. Polymorphisms in the retinoic acid-1 like-receptor family of genes and their association with clinical outcome of dengue virus infection. Arch Virol. 2015;160(6):1555–60.CrossRefPubMed
80.
Zurück zum Zitat Alagarasu K, Bachal RV, Damle I, Shah PS, Cecilia D. Association of FCGR2A p.R131H and CCL2 c.-2518 A>G gene variants with thrombocytopenia in patients with dengue virus infection. Hum Immunol. 2015;76(11):819–22.CrossRefPubMed Alagarasu K, Bachal RV, Damle I, Shah PS, Cecilia D. Association of FCGR2A p.R131H and CCL2 c.-2518 A>G gene variants with thrombocytopenia in patients with dengue virus infection. Hum Immunol. 2015;76(11):819–22.CrossRefPubMed
81.
Zurück zum Zitat Garcia G, Sierra B, Perez AB, Aguirre E, Rosado I, Gonzalez N, Izquierdo A, Pupo M, Danay Diaz DR, Sanchez L, et al. Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphism. American Journal of Tropical Medicine & Hygiene. 2010;82(6):1153–6.CrossRef Garcia G, Sierra B, Perez AB, Aguirre E, Rosado I, Gonzalez N, Izquierdo A, Pupo M, Danay Diaz DR, Sanchez L, et al. Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphism. American Journal of Tropical Medicine & Hygiene. 2010;82(6):1153–6.CrossRef
82.
Zurück zum Zitat Loke H, Bethell D, Phuong CX, Day N, White N, Farrar J, Hill A. Susceptibility to dengue hemorrhagic fever in Vietnam: evidence of an association with variation in the vitamin d receptor and fc gamma receptor IIa genes. American Journal of Tropical Medicine & Hygiene. 2002;67(1):102–6.CrossRef Loke H, Bethell D, Phuong CX, Day N, White N, Farrar J, Hill A. Susceptibility to dengue hemorrhagic fever in Vietnam: evidence of an association with variation in the vitamin d receptor and fc gamma receptor IIa genes. American Journal of Tropical Medicine & Hygiene. 2002;67(1):102–6.CrossRef
83.
Zurück zum Zitat Mohsin SN, Mahmood S, Amar A, Ghafoor F, Raza SM, Saleem M. Association of FcgammaRIIa polymorphism with clinical outcome of dengue infection: first insight from Pakistan. American Journal of Tropical Medicine & Hygiene. 2015;93(4):691–6.CrossRef Mohsin SN, Mahmood S, Amar A, Ghafoor F, Raza SM, Saleem M. Association of FcgammaRIIa polymorphism with clinical outcome of dengue infection: first insight from Pakistan. American Journal of Tropical Medicine & Hygiene. 2015;93(4):691–6.CrossRef
84.
Zurück zum Zitat Soundravally R, Hoti SL. Immunopathogenesis of dengue hemorrhagic fever and shock syndrome: role of TAP and HPA gene polymorphism. Hum Immunol. 2007;68(12):973–9.CrossRefPubMed Soundravally R, Hoti SL. Immunopathogenesis of dengue hemorrhagic fever and shock syndrome: role of TAP and HPA gene polymorphism. Hum Immunol. 2007;68(12):973–9.CrossRefPubMed
85.
Zurück zum Zitat Feitosa RNM, Vallinoto ACR, Vasconcelos PFDC, Azevedo RDSDS, Azevedo VN, MacHado LFA, Lima SS, Ishak MDOG, Ishak R. Gene polymorphisms and serum levels of pro- and anti-inflammatory markers in dengue viral infections. Viral Immunol. 2016;29(7):379–88.CrossRefPubMed Feitosa RNM, Vallinoto ACR, Vasconcelos PFDC, Azevedo RDSDS, Azevedo VN, MacHado LFA, Lima SS, Ishak MDOG, Ishak R. Gene polymorphisms and serum levels of pro- and anti-inflammatory markers in dengue viral infections. Viral Immunol. 2016;29(7):379–88.CrossRefPubMed
86.
Zurück zum Zitat Fernandez-Mestre MT, Gendzekhadze K, Rivas-Vetencourt P, Layrisse Z. TNF-alpha-308A allele, a possible severity risk factor of hemorrhagic manifestation in dengue fever patients. Tissue Antigens. 2004;64(4):469–72.CrossRefPubMed Fernandez-Mestre MT, Gendzekhadze K, Rivas-Vetencourt P, Layrisse Z. TNF-alpha-308A allele, a possible severity risk factor of hemorrhagic manifestation in dengue fever patients. Tissue Antigens. 2004;64(4):469–72.CrossRefPubMed
87.
Zurück zum Zitat Perez AB, Sierra B, Garcia G, Aguirre E, Babel N, Alvarez M, Sanchez L, Valdes L, Volk HD, Guzman MG. Tumor necrosis factor-alpha, transforming growth factor-beta1, and interleukin-10 gene polymorphisms: implication in protection or susceptibility to dengue hemorrhagic fever. Hum Immunol. 2010;71(11):1135–40.CrossRefPubMed Perez AB, Sierra B, Garcia G, Aguirre E, Babel N, Alvarez M, Sanchez L, Valdes L, Volk HD, Guzman MG. Tumor necrosis factor-alpha, transforming growth factor-beta1, and interleukin-10 gene polymorphisms: implication in protection or susceptibility to dengue hemorrhagic fever. Hum Immunol. 2010;71(11):1135–40.CrossRefPubMed
88.
Zurück zum Zitat Cansancao IF, do Carmo AP, Leite RD, Portela RD, de Sa Leitao Paiva Junior S, de Queiroz Balbino V, Rabenhorst SH. Association of genetic polymorphisms of IL1beta −511 C>T, IL1RN VNTR 86 bp, IL6–174 G>C, IL10–819 C>T and TNFalpha −308 G>A, involved in symptomatic patients with dengue in Brazil. Inflamm Res. 2016;65(11):925–32.CrossRefPubMed Cansancao IF, do Carmo AP, Leite RD, Portela RD, de Sa Leitao Paiva Junior S, de Queiroz Balbino V, Rabenhorst SH. Association of genetic polymorphisms of IL1beta −511 C>T, IL1RN VNTR 86 bp, IL6–174 G>C, IL10–819 C>T and TNFalpha −308 G>A, involved in symptomatic patients with dengue in Brazil. Inflamm Res. 2016;65(11):925–32.CrossRefPubMed
89.
Zurück zum Zitat Sa-Ngasang A, Ohashi J, Naka I, Anantapreecha S, Sawanpanyalert P, Patarapotikul J. Association of IL1B -31C/T and IL1RA variable number of an 86-bp tandem repeat with dengue shock syndrome in Thailand. J Infect Dis. 2014;210(1):138–45.CrossRefPubMed Sa-Ngasang A, Ohashi J, Naka I, Anantapreecha S, Sawanpanyalert P, Patarapotikul J. Association of IL1B -31C/T and IL1RA variable number of an 86-bp tandem repeat with dengue shock syndrome in Thailand. J Infect Dis. 2014;210(1):138–45.CrossRefPubMed
90.
Zurück zum Zitat Moreira ST, Cardoso DM, Visentainer JE, Fonzar UJV, Moliterno RA. The possible protective role of the Il6<sup>-174GC</sup> genotype in Dengue Fever. Open Tropical Medicine Journal. 2008;1:87–91.CrossRef Moreira ST, Cardoso DM, Visentainer JE, Fonzar UJV, Moliterno RA. The possible protective role of the Il6<sup>-174GC</sup> genotype in Dengue Fever. Open Tropical Medicine Journal. 2008;1:87–91.CrossRef
91.
Zurück zum Zitat Sam SS, Teoh BT, Chinna K, AbuBakar S. High producing tumor necrosis factor alpha gene alleles in protection against severe manifestations of dengue. Int J Med Sci. 2015;12(2):177–86.CrossRefPubMedPubMedCentral Sam SS, Teoh BT, Chinna K, AbuBakar S. High producing tumor necrosis factor alpha gene alleles in protection against severe manifestations of dengue. Int J Med Sci. 2015;12(2):177–86.CrossRefPubMedPubMedCentral
92.
Zurück zum Zitat Fernando AN, Malavige GN, Perera KL, Premawansa S, Ogg GS, De Silva AD. Polymorphisms of transporter associated with antigen presentation, tumor necrosis factor-alpha and Interleukin-10 and their implications for protection and susceptibility to severe forms of dengue fever in patients in Sri Lanka. J Global Infect Dis. 2015;7(4):157–64.CrossRef Fernando AN, Malavige GN, Perera KL, Premawansa S, Ogg GS, De Silva AD. Polymorphisms of transporter associated with antigen presentation, tumor necrosis factor-alpha and Interleukin-10 and their implications for protection and susceptibility to severe forms of dengue fever in patients in Sri Lanka. J Global Infect Dis. 2015;7(4):157–64.CrossRef
93.
Zurück zum Zitat Acioli-Santos B, Segat L, Dhalia R, Brito CA, Braga-Neto UM, Marques ET, Crovella S. MBL2 gene polymorphisms protect against development of thrombocytopenia associated with severe dengue phenotype. Hum Immunol. 2008;69(2):122–8.CrossRefPubMed Acioli-Santos B, Segat L, Dhalia R, Brito CA, Braga-Neto UM, Marques ET, Crovella S. MBL2 gene polymorphisms protect against development of thrombocytopenia associated with severe dengue phenotype. Hum Immunol. 2008;69(2):122–8.CrossRefPubMed
94.
Zurück zum Zitat Figueiredo GG, Cezar RD, Freire NM, Teixeira VG, Baptista P, Cordeiro M, Carmo RF, Vasconcelos LR, Moura P. Mannose-binding lectin gene (MBL2) polymorphisms related to the mannose-binding lectin low levels are associated to dengue disease severity. Hum Immunol. 2016;77(7):571–5.CrossRefPubMed Figueiredo GG, Cezar RD, Freire NM, Teixeira VG, Baptista P, Cordeiro M, Carmo RF, Vasconcelos LR, Moura P. Mannose-binding lectin gene (MBL2) polymorphisms related to the mannose-binding lectin low levels are associated to dengue disease severity. Hum Immunol. 2016;77(7):571–5.CrossRefPubMed
95.
Zurück zum Zitat Dang TN, Naka I, Sa-Ngasang A, Anantapreecha S, Chanama S, Wichukchinda N, Sawanpanyalert P, Patarapotikul J, Tsuchiya N, Ohashi J. A replication study confirms the association of GWAS-identified SNPs at MICB and PLCE1 in Thai patients with dengue shock syndrome. BMC Medical Genetics. 2014;15:58.CrossRefPubMedPubMedCentral Dang TN, Naka I, Sa-Ngasang A, Anantapreecha S, Chanama S, Wichukchinda N, Sawanpanyalert P, Patarapotikul J, Tsuchiya N, Ohashi J. A replication study confirms the association of GWAS-identified SNPs at MICB and PLCE1 in Thai patients with dengue shock syndrome. BMC Medical Genetics. 2014;15:58.CrossRefPubMedPubMedCentral
96.
Zurück zum Zitat Khor CC, Chau TN, Pang J, Davila S, Long HT, Ong RT, Dunstan SJ, Wills B, Farrar J, Van Tram T, et al. Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. Nat Genet. 2011;43(11):1139–41.CrossRefPubMedPubMedCentral Khor CC, Chau TN, Pang J, Davila S, Long HT, Ong RT, Dunstan SJ, Wills B, Farrar J, Van Tram T, et al. Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. Nat Genet. 2011;43(11):1139–41.CrossRefPubMedPubMedCentral
97.
Zurück zum Zitat Whitehorn J, Chau TN, Nguyet NM, Kien DT, Quyen NT, Trung DT, Pang J, Wills B, Van Vinh Chau N, Farrar J, et al. Genetic variants of MICB and PLCE1 and associations with non-severe dengue. PLoS ONE [Electronic Resource]. 2013;8(3):e59067.CrossRef Whitehorn J, Chau TN, Nguyet NM, Kien DT, Quyen NT, Trung DT, Pang J, Wills B, Van Vinh Chau N, Farrar J, et al. Genetic variants of MICB and PLCE1 and associations with non-severe dengue. PLoS ONE [Electronic Resource]. 2013;8(3):e59067.CrossRef
98.
Zurück zum Zitat Sierra B, Triska P, Soares P, Garcia G, Perez AB, Aguirre E, Oliveira M, Cavadas B, Regnault B, Alvarez M, et al. OSBPL10, RXRA and lipid metabolism confer African-ancestry protection against dengue haemorrhagic fever in admixed Cubans. PLoS Pathog. 2017;13(2):e1006220.CrossRefPubMedPubMedCentral Sierra B, Triska P, Soares P, Garcia G, Perez AB, Aguirre E, Oliveira M, Cavadas B, Regnault B, Alvarez M, et al. OSBPL10, RXRA and lipid metabolism confer African-ancestry protection against dengue haemorrhagic fever in admixed Cubans. PLoS Pathog. 2017;13(2):e1006220.CrossRefPubMedPubMedCentral
99.
Zurück zum Zitat Soundravally R, Hoti SL. Significance of transporter associated with antigen processing 2 (TAP2) gene polymorphisms in susceptibility to dengue viral infection. J Clin Immunol. 2008;28(3):256–62.CrossRefPubMed Soundravally R, Hoti SL. Significance of transporter associated with antigen processing 2 (TAP2) gene polymorphisms in susceptibility to dengue viral infection. J Clin Immunol. 2008;28(3):256–62.CrossRefPubMed
100.
Zurück zum Zitat Alagarasu K, Bachal RV, Memane RS, Shah PS, Cecilia D. Polymorphisms in RNA sensing toll like receptor genes and its association with clinical outcomes of dengue virus infection. Immunobiology. 2015;220(1):164–8.CrossRefPubMed Alagarasu K, Bachal RV, Memane RS, Shah PS, Cecilia D. Polymorphisms in RNA sensing toll like receptor genes and its association with clinical outcomes of dengue virus infection. Immunobiology. 2015;220(1):164–8.CrossRefPubMed
101.
Zurück zum Zitat Garcia-Trejo AR, Falcon-Lezama JA, Juarez-Palma L, Granados J, Zuniga-Ramos J, Rangel H, Barquera R, Vargas-Alarcon G, Ramos C. Tumor necrosis factor alpha promoter polymorphisms in Mexican patients with dengue fever. Acta Trop. 2011;120(1–2):67–71.CrossRefPubMed Garcia-Trejo AR, Falcon-Lezama JA, Juarez-Palma L, Granados J, Zuniga-Ramos J, Rangel H, Barquera R, Vargas-Alarcon G, Ramos C. Tumor necrosis factor alpha promoter polymorphisms in Mexican patients with dengue fever. Acta Trop. 2011;120(1–2):67–71.CrossRefPubMed
102.
Zurück zum Zitat Alagarasu K, Mulay AP, Singh R, Gavade VB, Shah PS, Cecilia D. Association of HLA-DRB1 and TNF genotypes with dengue hemorrhagic fever. Hum Immunol. 2013;74(5):610–7.CrossRefPubMed Alagarasu K, Mulay AP, Singh R, Gavade VB, Shah PS, Cecilia D. Association of HLA-DRB1 and TNF genotypes with dengue hemorrhagic fever. Hum Immunol. 2013;74(5):610–7.CrossRefPubMed
103.
Zurück zum Zitat Chuansumrit A, Anantasit N, Sasanakul W, Chaiyaratana W, Tangnararatchakit K, Butthep P, Chunhakan S, Yoksan S. Tumour necrosis factor gene polymorphism in dengue infection: association with risk of bleeding. Paediatrics and International Child Health. 2013;33(2):97–101.CrossRefPubMed Chuansumrit A, Anantasit N, Sasanakul W, Chaiyaratana W, Tangnararatchakit K, Butthep P, Chunhakan S, Yoksan S. Tumour necrosis factor gene polymorphism in dengue infection: association with risk of bleeding. Paediatrics and International Child Health. 2013;33(2):97–101.CrossRefPubMed
104.
Zurück zum Zitat Djamiatun K, Ferwerda B, Netea MG, van der Ven AJ, Dolmans WM, Faradz SM. Toll-like receptor 4 polymorphisms in dengue virus-infected children. American Journal of Tropical Medicine & Hygiene. 2011;85(2):352–4.CrossRef Djamiatun K, Ferwerda B, Netea MG, van der Ven AJ, Dolmans WM, Faradz SM. Toll-like receptor 4 polymorphisms in dengue virus-infected children. American Journal of Tropical Medicine & Hygiene. 2011;85(2):352–4.CrossRef
105.
Zurück zum Zitat Swati S, Singh SK, Kavita K, Nikky N, Dhole TN, Rajesh K, Saba H. Analysis of TLR4 (Asp299 Gly and Thr399Ile) gene polymorphisms and mRNA level in patients with dengue infection: a case-control study. Infect Genet Evol. 2016;43:412–7.CrossRef Swati S, Singh SK, Kavita K, Nikky N, Dhole TN, Rajesh K, Saba H. Analysis of TLR4 (Asp299 Gly and Thr399Ile) gene polymorphisms and mRNA level in patients with dengue infection: a case-control study. Infect Genet Evol. 2016;43:412–7.CrossRef
106.
Zurück zum Zitat Alagarasu K, Honap T, Mulay AP, Bachal RV, Shah PS, Cecilia D. Association of vitamin D receptor gene polymorphisms with clinical outcomes of dengue virus infection. Hum Immunol. 2012;73(11):1194–9.CrossRefPubMed Alagarasu K, Honap T, Mulay AP, Bachal RV, Shah PS, Cecilia D. Association of vitamin D receptor gene polymorphisms with clinical outcomes of dengue virus infection. Hum Immunol. 2012;73(11):1194–9.CrossRefPubMed
Metadaten
Titel
Identification of genetic variants associated with dengue or West Nile virus disease: a systematic review and meta-analysis
verfasst von
Megan E. Cahill
Samantha Conley
Andrew T. DeWan
Ruth R. Montgomery
Publikationsdatum
01.12.2018
Verlag
BioMed Central
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2018
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-018-3186-6

Weitere Artikel der Ausgabe 1/2018

BMC Infectious Diseases 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.